CLEU20105/ S1905/ Kristen O'Dwyer
Basic Study Information
Purpose:Location: University of Rochester
This phase II trial studies how well OBI-3424 works in treating patients with T-cell
acute lymphoblastic leukemia that has come back (relapsed) or does not response to
treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in different
ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount
of leukemia in the body.
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amber Johnson
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search